环状RNA与肿瘤耐药的关系

国际肿瘤学杂志››2020,Vol. 47››Issue (4): 223-226.doi:10.3760/cma.j.cn371439-20191031-00006

袁霜, 孙笑, 王丽华()

上海交通大学医学院附属国际和平妇幼保健院妇科肿瘤科 200030

收稿日期:2019-10-31修回日期:2020-01-03出版日期:2020-04-08发布日期:2020-05-26
通讯作者:王丽华 E-mail:drwanglh0420@163.com
基金资助:
国家自然科学基金(81572547)

Relationship between circular RNA and cancer drug resistance

Yuan Shuang, Sun Xiao, Wang Lihua()

Department of Gynecologic Oncology, International Peace Maternity & Child Health Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China

Received:2019-10-31Revised:2020-01-03Online:2020-04-08Published:2020-05-26
Contact:Wang Lihua E-mail:drwanglh0420@163.com
Supported by:
National Natural Science Foundation of China(81572547)

摘要/Abstract

摘要：

环状RNA是非编码RNA家族的成员,可以多种方式参与生物学功能,如细胞增殖、细胞周期、侵袭和转移等。近年来研究发现,环状RNA可以通过海绵吸附微小RNA和RNA结合蛋白参与转录后调控,从而影响肿瘤耐药过程中的DNA修复、凋亡、增殖、细胞转运,以及介导肿瘤耐药的细胞内酶,进而在肿瘤耐药中发挥重要调节作用。研究证实通过干扰环状RNA的表达,可以提高肿瘤对药物的敏感性,提示环状RNA可能为抗肿瘤药物耐药性的研究提供新的靶点。

关键词:微RNAs,肿瘤,抗药性

Abstract:

Circular RNA is a member of the non-coding RNA family and can participate in biological functions in many ways, such as cell proliferation, cell cycle, invasion and metastasis. Recent studies have shown that circular RNA can be involved in post transcriptional regulation by sponge miRNA and RNA binding proteins. Thus, it can affect DNA repair, apoptosis, proliferation, cell transport, and intracellular enzymes those mediate drug resistance, so as to play an important regulatory role in drug resistance. Moreover, it has been confirmed that interfering with the expression of circular RNA can improve the sensitivity of cancer to drugs, suggesting that circular RNA may provide a new target for the study of drug resistance of cancer.

Key words:MicroRNAs,Neoplasms,Drug resistance

袁霜, 孙笑, 王丽华. 环状RNA与肿瘤耐药的关系[J]. 国际肿瘤学杂志, 2020, 47(4): 223-226.

Yuan Shuang, Sun Xiao, Wang Lihua. Relationship between circular RNA and cancer drug resistance[J]. Journal of International Oncology, 2020, 47(4): 223-226.

参考文献31

[1]	Chen LL . The biogenesis and emerging roles of circular RNAs[J]. Nat Rev Mol cell Biol, 2016,17(4):205-211. DOI: 10.1038/nrm.2015.32. doi:10.1038/nrm.2015.32
[2]	Liu J, Liu T, Wang X , et al. Circles reshaping the RNA world: from waste to treasure[J]. Mol Cancer, 2017,16(1):58. DOI: 10.1186/s12943-017-0630-y. doi:10.1186/s12943-017-0630-y
[3]	Meng S, Zhou H, Feng Z , et al. CircRNA: functions and properties of a novel potential biomarker for cancer[J]. Mol Cancer, 2017,16(1):94. DOI: 10.1186/s12943-017-0663-2. doi:10.1186/s12943-017-0663-2
[4]	Shang Q, Yang Z, Jia R , et al. The novel roles of circRNAs in human cancer[J]. Mol Cancer, 2019,18(1):6. DOI: 10.1186/s12943-018-0934-6. doi:10.1186/s12943-018-0934-6
[5]	Kleaveland B, Shi CY, Stefano J , et al. A network of noncoding regulatory RNAs acts in the mammalian brain[J]. Cell, 2018, 174(2): 350-362.e17. DOI: 10.1016/j.cell.2018.05.022. doi:10.1016/j.cell.2018.05.022
[6]	Yu CY, Kuo HC . The emerging roles and functions of circular RNAs and their generation[J]. J Biomed Sci, 2019,26(1):29. DOI: 10.1186/s12929-019-0523-z. doi:10.1186/s12929-019-0523-z
[7]	Du WW, Yang W, Chen Y , et al. Foxo3 circular RNA promotes cardiac senescence by modulating multiple factors associated with stress and senescence responses[J]. Eur Heart J, 2016,38(18):1402-1412. DOI: 10.1093/eurheartj/ehw001.
[8]	Yang Y, Gao X, Zhang M , et al. Novel role of FBXW7 circular RNA in repressing glioma tumorigenesis[J]. J Natl Cancer Inst, 2018,110(3). DOI: 10.1093/jnci/djx166.
[9]	Wang D, Yang S, Wang H , et al. The progress of circular RNAs in various tumors[J]. Am J Transl Res, 2018,10(6):1571-1582.
[10]	Wei Y, Chen X, Liang C , et al. A noncoding regulatory RNAs network driven by circ-CDYL acts specifically in the early stages hepatocellular carcinoma[J]. Hepatology, 2020,71(1):130-147. DOI: 10.1002/hep.30795. doi:10.1002/hep.v71.1
[11]	Gavande NS, Vandervere-Carozza PS, Hinshaw HD , et al. DNA repair targeted therapy: the past or future of cancer treatment?[J]. Pharmacol Ther, 2016,160:65-83. DOI: 10.1016/j.pharmthera.2016.02.003. doi:10.1016/j.pharmthera.2016.02.003
[12]	Yin JY, Zhang JT, Zhang W , et al. eIF3a: a new anticancer drug target in the eIF family[J]. Cancer Lett, 2018,412:81-87. DOI: 10.1016/j.canlet.2017.09.055. doi:10.1016/j.canlet.2017.09.055
[13]	Fang C, Chen YX, Wu NY , et al. MiR-488 inhibits proliferation and cisplatin sensibility in non-small-cell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway[J]. Sci Rep, 2017,7:40384. DOI: 10.1038/srep40384. doi:10.1038/srep40384
[14]	Huang MS, Yuan FQ, Gao Y , et al. Circular RNA screening from EIF3a in lung cancer[J]. Cancer Med, 2019,8(9):4159-4168. DOI: 10.1002/cam4.2338.
[15]	Su Y, Yang W, Jiang N , et al. Hypoxia-elevated circELP3 contributes to bladder cancer progression and cisplatin resistance[J]. Int J Biol Sci, 2019,15(2):441-452. DOI: 10.7150/ijbs.26826. doi:10.7150/ijbs.26826
[16]	Manic G, Sistigu A, Corradi F , et al. Replication stress response in cancer stem cells as a target for chemotherapy[J]. Semin Cancer Biol, 2018,53:31-41. DOI: 10.1016/j.semcancer.2018.08.003. doi:10.1016/j.semcancer.2018.08.003
[17]	Sang Y, Chen B, Song X , et al. CircRNA_0025202 regulates tamoxifen sensitivity and tumor progression via regulating the miR-182-5p/FOXO3a axis in breast cancer[J]. Mol Ther, 2019,27(9):1638-1652. DOI: 10.1016/j.ymthe.2019.05.011. doi:10.1016/j.ymthe.2019.05.011
[18]	Liu Y, Ao X, Ding W , et al. Critical role of FOXO3a in carcinogenesis[J]. Mol Cancer, 2018,17(1):104. DOI: 10.1186/s12943-018-0856-3. doi:10.1186/s12943-018-0856-3
[19]	Rathore R, McCallum JE, Varghese E, et al. Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)[J]. Apoptosis, 2017,22(7):898-919. DOI: 10.1007/s10495-017-1375-1. doi:10.1007/s10495-017-1375-1
[20]	Shang J, Chen WM, Wang ZH , et al. CircPAN3 mediates drug resistance in acute myeloid leukemia through the miR-153-5p/miR-183-5p-XIAP axis[J]. Exp Hematol, 2019,70:42-54, e3. DOI: 10.1016/j.exphem.2018.10.011. doi:10.1016/j.exphem.2018.10.011
[21]	Abu N, Hon KW, Jeyaraman S , et al. Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer[J]. Epigenomics, 2019,11(8):875-884. DOI: 10.2217/epi-2019-0042. doi:10.2217/epi-2019-0042
[22]	Zhou Y, Zheng X, Xu B , et al. Circular RNA hsa_circ_0004015 regulates the proliferation, invasion, and TKI drug resistance of non-small cell lung cancer by miR-1183/PDPK1 signaling pathway[J]. Biochem Biophys Res Commun, 2019,508(2):527-535. DOI: 10.1016/j.bbrc.2018.11.157. doi:10.1016/j.bbrc.2018.11.157
[23]	Bermúdez M, Aguilar-Medina M, Lizárraga-Verdugo E , et al. LncRNAs as regulators of autophagy and drug resistance in colorectal cancer[J]. Front Oncol, 2019,9:1008. DOI: 10.3389/fonc.2019.01008. doi:10.3389/fonc.2019.01008
[24]	Miao Y, Zheng W, Li N , et al. MicroRNA-130b targets PTEN to mediate drug resistance and proliferation of breast cancer cells via the PI3K/Akt signaling pathway[J]. Sci Rep, 2017,7:41942. DOI: 10.1038/srep41942. doi:10.1038/srep41942
[25]	Li D, Mullinax JE, Aiken T , et al. Loss of PDPK1 abrogates resistance to gemcitabine in label-retaining pancreatic cancer cells[J]. BMC Cancer, 2018,18(1):772. DOI: 10.1186/s12885-018-4690-1. doi:10.1186/s12885-018-4690-1
[26]	Zhu KP, Ma XL, Zhang CL . Overexpressed circPVT1, a potential new circular RNA biomarker, contributes to doxorubicin and cisplatin resistance of osteosarcoma cells by regulating ABCB1[J]. Int J Biol Sci, 2018,14(3):321-330. DOI: 10.7150/ijbs.24360. doi:10.7150/ijbs.24360
[27]	Yu W, Peng W, Sha H , et al. Hsa_circ_0003998 promotes chemoresistance via modulation of miR-326 in lung adenocarcinoma cells[J]. Oncol Res, 2019,27(5):623-628. DOI: 10.3727/096504018X15420734828058. doi:10.3727/096504018X15420734828058
[28]	Pasello M, Giudice AM, Scotlandi K. The ABC subfamily A transporters: multifaceted players with incipient potentialities in cancer[J]. Semin Cancer Biol, 2019, Inpress. DOI: 10.1016/j.semcancer.2019.10.004.
[29]	Du Y, Shen L, Zhang W , et al. Functional analyses of microRNA-326 in breast cancer development[J]. Biosci Rep, 2019, 39(7). pii: BSR20190787. DOI: 10.1042/BSR20190787.
[30]	Allocati N, Masulli M, Di Ilio C , et al. Glutathione transferases: substrates, inihibitors and pro-drugs in cancer and neurodegenerative diseases[J]. Oncogenesis, 2018,7(1):8. DOI: 10.1038/s41389-017-0025-3. doi:10.1038/s41389-017-0025-3
[31]	Zhu KP, Zhang CL, Ma XL , et al. Analyzing the interactions of mRNAs and ncRNAs to predict competing endogenous RNA networks in osteosarcoma chemo-resistance[J]. Mol Ther, 2019,27(3):518-530. DOI: 10.1016/j.ymthe.2019.01.001. doi:10.1016/j.ymthe.2019.01.001